Sarepta to release 3-year data for muscle dystrophy gene therapy; shares rise

Sarepta Therapeutics

26/01/2026 10:47

** Shares of genetic medicine maker Sarepta Therapeutics SRPT.O rise 6.4% to $22.49 premarket

** Co says it will present three‑year results from its EMBARK trial of Elevidys, its gene therapy for Duchenne muscular dystrophy (DMD) — a muscle‑wasting disease

**  Elevidys is designed to deliver a shortened dystrophin gene to help slow progressive muscle decline, co says

**  SRPT says results will be shared via webcast on January 26 at 8:30 a.m. ET

** Trial tested Elevidys against placebo in boys aged between 4 and 7 years who had not yet lost the ability to walk due to DMD, co says

** Shares fell ~82% in 2025

 (Reporting by Sahil Pandey in Bengaluru)

 ((Sahil.Pandey@thomsonreuters.com))